FDA Adverse Event Injury Summary report: N

ENDEAVOR RX

MDR report key: 3860971 · Received June 10, 2014

Report

Report Number
9612164-2014-00607
Event Type
Injury
Date Received
June 10, 2014
Date of Event
February 26, 2013
Report Date
May 12, 2014
Manufacturer
MEDTRONIC IRELAND
Product Code
NIQ
PMA / PMN Number
P060033
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4). ROOT CAUSE UNDETERMINED DEVICE/IMAGES NOT RETURNED. STENT THROMBOSIS. NO RESULTS AVAILABLE SINCE NO EVALUATION PERFORMED. DEVICE NOT RETURNED FOR EVALUATION. RESULTS: STENT THROMBOSIS. DEVICE NOT RETURNED. ROOT CAUSE UNDETERMINED DEVICE/IMAGES NOT RETURNED. AGE AT TIME OF EVENT IS THE AVERAGE AGE OF THE PATIENTS. EVENT DATE = DATE OF PUBLICATION. TITLE OF ARTICLE THREE YEAR CLINICAL OUTCOMES WITH ZOTAROLIMUS (ENDEAVOR) DRUG-ELUTING STENTS IN AN UNRESTRICTED CONTEMPORARY PRACTICE. HTTP://DX.DOI.ORG/10.1016/J.IJCARD.2013.01.234.

Description of Event or Problem · 1

PATIENTS RECEIVING ENDEAVOR STENTS BETWEEN JUNE 2005 AND FEBRUARY 2007 WERE INCLUDED FOR ANALYSIS. IN TOTAL WE IDENTIFIED 494 PATIENTS WITH 625 LESIONS TREATED WITH 717 ZESS. THIS COHORT INCLUDED A LARGE PERCENTAGE OF HIGH-RISK PATIENTS, INCLUDING PATIENTS WITH DIABETES 31.2%), TARGET LESIONS IN VESSELS LESS THAN 3.0 MM(47.5%), LESIONS GREATER THAN 20 MIN LENGTH (45.5%) AND PATIENTS BEING TREATED FOR ACS (66.2%). ADDITIONALLY, A LARGE NUMBER OF PATIENTS WITH PRIOR PCI (25.3%) AND BYPASS SURGERY (10.3%) WERE REPRESENTED IN THE COHORT. INTERESTINGLY, DESPITE THE PREVALENCE OF HIGH-RISK PATIENTS, THE CUMULATIVE RATES OF CARDIAC DEATHS (4.5%), MIS (6.8%), AND ST (0.9%) WERE EXCEEDINGLY LOW AT 36 MONTHS. THREE CASES OF ARC DEFINITE STENT THROMBOSIS OCCURRED DURING THE STUDY PERIOD, WHICH OCCURRED IN THE FIRST 12 MONTHS. THE 36-MONTH CUMULATIVE RATE FOR TVR WAS 12.2%

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
342244 ENDEAVOR RX STENT, CORONARY, DRUG-ELUTING NIQ MEDTRONIC IRELAND

Patients

Seq Age Sex Outcome Treatment
1 00065 YR